Drilldown: Medicines

None (3) · Methylphenidate (1)

Aimovig (1) · Ajovy (1) · Ritalin, Ritalin LA, Concerta, Metadate CD, Daytrana, Quillivant XR (1) · Zavzpret (zavegepant) (1)

Anti-CGRP ligand monoclonal antibody (1) · Anti-CGRP receptor monoclonal antibody (1) · CGRP receptor antagonist (1) · Gepant (1) · NDRI (1) · Psychostimulant (1)

Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) · Humanized IgG2 monoclonal antibody binding the CGRP receptor (not the peptide); blocks CGRP-mediated vasodilation and nociceptive signaling (1) · Norepinephrine–dopamine reuptake inhibition (DAT, NET) (1) · Small-molecule CGRP receptor antagonist; intranasal formulation (1)

None · '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' · '"`UNIQ--vote-00000008-QINU`"', '"`UNIQ--vote-00000009-QINU`"' · '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' · '"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"' · '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"' · '"`UNIQ--vote-00000006-QINU`"' · '"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"' · '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"' · '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"', '"`UNIQ--vote-00000028-QINU`"' · '"`UNIQ--vote-00000013-QINU`"', '"`UNIQ--vote-00000014-QINU`"' · '"`UNIQ--vote-00000015-QINU`"', '"`UNIQ--vote-00000016-QINU`"' · Preventive treatment of migraine in adults (episodic and chronic) · '"`UNIQ--vote-00000015-QINU`"', '"`UNIQ--vote-00000016-QINU`"', '"`UNIQ--vote-00000017-QINU`"' · (investigational) '"`UNIQ--vote-000000EF-QINU`"', '"`UNIQ--vote-000000F0-QINU`"', '"`UNIQ--vote-000000F1-QINU`"', '"`UNIQ--vote-000000F2-QINU`"', '"`UNIQ--vote-000000F3-QINU`"' · Acute treatment of migraine with or without aura in adults · ADHD in children (6+), adolescents, and adults (FDA-approved 2021 for pediatric, 2022 for adult) · ADHD, narcolepsy · Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD. · Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024

Other values:

Search

None (1) · 10 mg (one spray) intranasally in one nostril (1) · 225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) · 70 mg SC monthly; may increase to 140 mg monthly (1)

None (1) · 10 mg/spray nasal solution (1) · 225 mg/1.5 mL prefilled syringe or autoinjector (1) · 70 mg/mL or 140 mg/mL prefilled autoinjector (1)

None (1) · 10 mg per 24 h (1) · 140 mg/month (1) · 675 mg/quarter (1)

Intranasal (1) · Oral (1) · Subcutaneous (2) · transdermal (1)

20–60 min (oral) (1) · Onset of preventive effect over weeks; some patients respond after first dose (1) · Over weeks (1) · Pain relief reported within 15 min in trials (1)

IR 3–5 h; LA/SR 6–8 h; Concerta 10–12 h; Daytrana ~9 h wear time (1) · Monthly dosing (1) · Monthly or quarterly dosing (1) · ~48 h sustained pain freedom in responders (1)

2–3 h (parent compound) (1) · ~28 days (1) · ~31 days (1) · ~6.6 h (1)

Not formally established (1) · ~30% (high first-pass) (1) · ~5% intranasal (1) · ~82% SC (1)

Limited data; avoid (3) · Pregnancy categories were retired by FDA in 2015. Limited reproductive data with small observational signal for cardiac malformations; risk-benefit decision, with many patients deferring ADHD treatment during pregnancy. See pregnancy_details for the full discussion. (1)

Rx (3) · Schedule II (1)